Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy
HIV Medicine · 2026
DOI: 10.1111/hiv.70128 ↗Kurz gefasst
Fachartikel in der Zeitschrift HIV Medicine, 2026. Verfasst von Tali Faggiano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, University of California, San Diego, San Diego, California, USA. Hauptthemen laut MEDLINE: HIV Infections, Rilpivirine, Pyridones, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Evaluate factors associated with discontinuation of long‐acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) and describe virologic outcomes in those that returned to oral antiretroviral therapy (ART).
Methods
This is a retrospective cohort study at a single‐centre primary care HIV clinic. Included were adults who received at least one injection of LAI CAB/RPV between April 2021 and March 2024. Characteristics were compared between those that continued LAI CAB/RPV and those that discontinued treatment during the study period. HIV viral load (VL) outcomes were evaluated in those that returned to oral ART and included the most recent VL in the range of 1–24 weeks, 24–48 weeks and the most recently documented VL through September 2024.
Results
A total of 92 and 346 patients were included in the discontinuation and continuation cohorts, respectively. Being male sex assigned at birth and having psychiatric disease was associated with continuing LAI CAB/RPV, whereas having active substance use and being on a multi‐class regimen prior to initiation of LAI CAB/RPV was associated with discontinuation. In those with VL data after resuming oral ART, the percentage of those with HIV VL
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Department, University of California, San Diego, San Diego, California, USA.
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, San Diego, California, USA.
- Owen Clinic, University of California, San Diego, San Diego, California, USA.
Zitieren
APA
Faggiano, T., Yin, J., Patel, N., Karim, A., Abulhosn, K., Bamford, L., & Hill, L. (2026). Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy. HIV Medicine. https://doi.org/10.1111/hiv.70128
Vancouver
Faggiano T, Yin J, Patel N, Karim A, Abulhosn K, Bamford L, et al. Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy. HIV Medicine. 2026. doi:10.1111/hiv.70128
BibTeX
@article{Faggiano2026,
author = {Faggiano, Tali and Yin, Jeffrey and Patel, Nimish and Karim, Afsana and Abulhosn, Kari and Bamford, Laura and Hill, Lucas},
title = {Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy},
journal = {HIV Medicine},
year = {2026},
doi = {10.1111/hiv.70128}
}
EUVIMED